Today announced that its VMS+ technology has been selected for use in AIRES (Artificial Intelligence Reconstruction of Echocardiography Study), a newly launched clinical research study at The Royal Wolverhampton NHS Trust in the United Kingdom. AIRES is described as a world-first study evaluating AI-enabled echocardiography specifically in oncology patients. The research will focus on patients undergoing chemotherapy for breast cancer, a population at risk of developing treatment-related heart complications. Ventripoint Diagnostics Ltd shares V.VPT are trading off $0.01 at $0.11.

Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=VPT%3ACC&qmodStoryID=6554407566180453

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.